⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711711 | 0.67 | — | — | |
| SCHEMBL5134172 | 0.52 | — | — | |
| SCHEMBL29539275 | 0.39 | — | — | |
| SCHEMBL29618966 | 0.39 | — | — | |
| SCHEMBL31195642 | 0.39 | — | — | |
| SCHEMBL31091764 | 0.32 | — | — | |
| SCHEMBL29786177 | 0.32 | — | — | |
| SCHEMBL3000562 | 0.32 | — | — | |
| SCHEMBL31140804 | 0.32 | — | — | |
| SCHEMBL30522172 | 0.32 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347558-A1 | 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS | ReWind Therapeutics NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347541-A2 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | Telix Pharmaceuticals (Innovations) Pty Ltd (AU) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024062043-A1 | SUBSTITUTED PHENOTHIAZINES AS FERROPTOSIS INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024059119-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | SOLIOME, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20240059688-A1 | CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER | LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) | 2024-02-22 | — | — | US | disclosed |
| WO-2024033479-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2024-02-15 | — | — | WO | disclosed |
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-9750745-B2 | 2,7-diazaspiro[3.5]nonane compounds | REMYND NV (BE) | 2017-09-05 | — | — | US | disclosed |
| US-20170157137-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9617264-B2 | 2,7-diazaspiro[3.5]nonane compounds | REMYND NV (BE) | 2017-04-11 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-3119782-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119774-A1 | OXADIAZOLE COMPOUNDS | reMynd NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| US-20170015665-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2017-01-19 | — | — | US | disclosed |
| WO-2016083490-A1 | COMPOUNDS FOR THE TREATMENT OF AMYLOID-ASSOCIATED DISEASES | REMYND NV (BE) | 2016-06-02 | — | — | WO | disclosed |
| WO-2015140132-A1 | 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |